四川双马(000935)2025年半年报点评：市场向好投资改善 医药资产带来新机遇

Core Insights - The company experienced significant growth in H1 2025, primarily due to a turnaround in investment income and revenue from the acquisition of Shenzhen JianYuan in the pharmaceutical sector [1][2]. Financial Performance - Adjusted revenue and net profit for H1 2025 were 665 million and 129 million yuan, respectively, reflecting year-on-year increases of 65% and 13% [2]. - Investment income, including investment gains and fair value changes, reached 36 million yuan, recovering from a negative 79 million yuan in the same period of 2024 [2]. - Private equity management fee income decreased by 5.07% to 210 million yuan, while revenue from the building materials segment grew by 4.88% to 274 million yuan [2]. - Revenue from the biopharmaceutical segment was 145 million yuan, driven by the acquisition of Shenzhen JianYuan, which contributed to both business and investment income growth [2]. Strategic Moves - The acquisition of Shenzhen JianYuan represents a deepened commitment to the biopharmaceutical industry, focusing on the research and sales of peptide products, which is expected to drive future revenue growth [3]. - The company is also looking to enhance its project portfolio by focusing on innovative technology sectors such as new industrialization and artificial intelligence [3]. Market Outlook - Recent improvements in the capital market are favorable for the company's project exits, which will accelerate the realization of returns from follow-on investments and performance compensation [3][4].